Table 4.
Variable | CGC n = 12 | CyGC n = 20 | P* |
---|---|---|---|
PAD (mg/patient) |
|
|
|
8 weeks |
4200 |
1500 |
- |
12 weeks |
- |
2500 |
- |
Fasting hyperglycemia (≥5.60 mmol/L) |
|
|
|
Incidence, n (%) |
12 (100) |
10 (50) |
0.003* |
Plasma glucose (mmol/L) |
8.22 ± 3.79 |
6.50 ± 0.64 |
0.16 |
Prediabetes (≥5.60- < 7.00 mmol/L) |
|
|
|
Incidence, n (%) |
5 (41.6) |
6 (30) |
0.51 |
DM (fasting glycemia ≥7.00 mmol/L) |
|
|
|
Incidence, n (%) |
7 (58.3) |
4 (20) |
0.22 |
Plasma glucose (mmol/L) |
9.83 ± 4.39 |
7.11 ± 0.15 |
0.26 |
DM occurrence - week, n (%) |
|
|
|
First |
0 (0) |
0 (0) |
- |
Second to fourth |
5 (71.4) |
0 (0) |
- |
Fifth to eighth |
2 (28.5) |
4 (100) |
- |
Postprandial hyperglycemia |
|
|
|
Incidence, n (%) | 1 (8.3) | 4 (20) | 0.62 |
All data are reported in total number of subjects and (%) or mean ± SD.
CGC, continuous glucocorticoid regimen; CyGC, cyclic glucocorticoid regimen; PAD, prednisone accumulative dose; DM, diabetes mellitus.
*Significant P value ≤0.05.